Shares of hVIVO plc (LON:HVO - Get Free Report) rose 23% during mid-day trading on Monday . The company traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). Approximately 24,253,932 shares traded hands during mid-day trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).
Analyst Ratings Changes
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.
View Our Latest Stock Report on HVO
hVIVO Trading Up 3.4%
The business's 50-day simple moving average is GBX 15.92 and its two-hundred day simple moving average is GBX 17.70. The firm has a market capitalization of £76.07 million, a price-to-earnings ratio of 4.43 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.
hVIVO (LON:HVO - Get Free Report) last posted its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current year.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Articles
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
